Phytoestrogen modulation of bone-related cytokines and its impact on cell viability in human prostate cancer cells

Life Sciences

Volumn 85, Issue 11-12, 2009, Pages 421-430

  Alonso, V ^a   Perez Martinez F C ^a   Calahorra, F J ^a,b   Esbrit, P ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Apoptosis; Osteomimetic; Phytoestrogens; Prostate cancer; PTHrP

Indexed keywords

CYTOKINE; DAIDZEIN; GENISTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE RELATED PROTEIN; PHYTOESTROGEN; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; TRANSCRIPTION FACTOR RUNX2; TRYPAN BLUE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE CELL; BONE METASTASIS; CANCER CELL CULTURE; CELL DEATH; CELL GROWTH; CELL INTERACTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METASTASIS POTENTIAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

BLOTTING, WESTERN; BONE AND BONES; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; FLOW CYTOMETRY; GENISTEIN; HUMANS; ISOFLAVONES; MALE; OSTEOPROTEGERIN; PARATHYROID HORMONE-RELATED PROTEIN; PHYTOESTROGENS; PROSTATIC NEOPLASMS; RANK LIGAND; RECEPTOR, PARATHYROID HORMONE, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSFECTION;

EID: 69449108087     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.07.005     Document Type: Article

References (48)

1. Albar J.P., De Miguel F., Esbrit P., Miranda R., Fernandez-Flores A., and Sarasa J.L. Immunohistochemical detection of parathyroid hormone-related protein in a rare variant of hepatic neoplasm (sclerosing hepatic carcinoma). Human Pathology 27 7 (1996) 728-731
2. Alonso V., de Gortázar A.R., Ardura J.A., Andrade-Zapata I., Alvarez-Arroyo M.V., and Esbrit P. Parathyroid hormone-related protein (107-139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-2. Journal of Cellular Physiology 217 3 (2008) 717-727
3. Asadi F., and Kukreja S. Parathyroid hormone-related protein in prostate cancer. Critical Reviews in Eukaryotic Gene Expression 15 1 (2005) 15-28
4. Asadi F., Farraj M., Sharifi R., et al. Enhanced expression of parathyroid hormonerelated protein in prostate cancer as compared with benign prostatic neoplasia. Human Pathology 27 12 (1996) 1319-1323
5. Bagi C.M. Targeting of therapeutic agents to bone to treat metastatic cancer. Advanced Drug Delivery Reviews 57 7 (2005) 995-1010
6. Bellido T., Ali A.A., Plotkin L.I., Fu Q., Gubrij I., Roberson P.K., Weinstein R.S., O Brien C.A., Manolagas S.C., and Jilka R.L. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. Journal of Biological Chemistry 278 50 (2003) 50259-50272
7. Blyth K., Vaillant F., Hanlon L., Mackay N., Bell M., Jenkins A., Neil J.C., and Cameron E.R. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Research 66 4 (2006) 2195-2201
8. Brown J.M., Corey E., Lee Z.D., True L.D., Yun T.J., Tondravi M., and Vessella R.L. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57 4 (2001) 611-616
9. Chen G., Sircar K., Aprikian A., Potti A., Goltzman D., and Rabbani S.A. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107 2 (2006) 289-298
10. Davis J.N., Singh B., Bhuiyan M., and Sarkar F.H. Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutrition and Cancer 32 3 (1998) 123-131
11. Davis D.A., Sarkar S.H., Hussain M., Li Y., and Sarkar F.H. Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer 6 (2006) 22
12. Deftos L.J. Prostate carcinoma: production of bioactive factors. Cancer 88 12 Suppl (2000) 3002-3008
13. Deftos L.J., Barken I., Burton D.W., et al. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochemical and Biophysical Research Communications 327 2 (2005) 468-472
14. Dennis L., Morton M.S., and Griffiths K. Diet and its preventive role in prostate disease. European Urology 35 5-6 (1999) 377-387
15. Dougherty K.M., Blomme E.A., Koh A.J., Henderson J.E., Pienta K.J., Rosol T.J., and McCauley L.K. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Research 59 23 (1999) 6015-6022
16. Ducy P., Starbuck M., Priemel M., Shen J., Pinero G., Geoffroy V., Amling M., and Karsenty G. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes & Development 13 8 (1999) 1025-1036
17. Eaton C.L., Wells J.M., Holen I., Croucher P.I., and Hamdy F.C. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 59 3 (2004) 304-310
18. Goltzman D. Osteolysis and cancer. Journal of Clinical Investigation 107 10 (2001) 1219-1220
19. Gujral A., Burton D.W., Terkeltaub R., et al. Parathyroid hormone-related protein induces interleukin-8 production by prostate cancer cells via a novel intracrine mechanism not mediated by its classical nuclear localization sequence. Cancer Research 61 5 (2001) 2282-2288
20. Holen I., Croucher P.I., Hamdy F.C., et al. Osteoprotegerein (OPG) is a survival factor for human prostate cancer cells. Cancer Research 62 6 (2002) 1619-1623
21. Holstead J.D., Nakashima T., Sanchez O.H., Kozieradzki I., Komarova S.V., Sarosi I., Morony S., Rubin E., Sarao R., Hojilla C.V., Komnenovic V., Kong Y.Y., Schreiber M., Dixon S.J., Sims S.M., Khokha R., Wada T., and Penninger J.M. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440 7084 (2006) 692-696
22. Huang J.C., S T., Pfleger L.L., Bencsik M., Halloran B.P., Bikle D.D., and Nissenson R.A. PTH differentially regulates expression of RANKL and OPG. Journal of Bone and Mineral Research 19 2 (2004) 235-244
23. Iddon J., Bundred N.J., Hoyland J., Downey S.E., Baird P., Salter D., McMahon R., and Freemont A.J. Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer. Journal of Pathology 191 2 (2000) 170-174
24. Inoue H., Nishimura K., Oka D., Nakai Y., Shiba M., Tokizane T., Arai Y., Nakayama M., Shimizu K., Takaha N., Nonomura N., and Okuyama A. Prostate cancer mediates osteoclastogenesis through two different pathways. Cancer Letter 223 1 (2005) 121-128
25. Jia T.L., Wang H.Z., Xie L.P., Wang X.Y., and Zhang R.Q. Daidzein enhances osteoblast growth that may be mediated by increased bone morphogenetic protein (BMP) production. Biochemical Pharmacology 65 5 (2003) 709-715
26. Koeneman K.S., Yeung F., and Chung L.W. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39 4 (1999) 246-261
27. Li Y., and Sarkar F.H. Inbition of nuclear factor kappaB activation in PC-3 cells by genistein is mediated via AKT signalling pathway. Clinical Cancer Research 8 7 (2002) 2369-2377
28. Li Y., Che M., Bhagat S., Ellis K.L., Kucuk O., Doerge D.R., Abrams J., Cher M.L., and Sarkar F.H. Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia 6 4 (2004) 354-363
29. Lin D.L., Tarnowski C.P., Zhang J., Dai J., Rohn E., Patel A.H., Morris M.D., and Keller E.T. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47 3 (2001) 212-221
30. Lucia M.S., and Torkko K.C. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. Journal of Urology 171 2 pt 2 (2004) 830-835
31. Magge P.J., McGlynn H., and Rowland I.R. Differential effects of isoflavones and lignans on invasiveness of MDA-MB-231 breast cancer cells in vitro. Cancer Letter 208 1 (2004) 35-41
32. Mansour A., McCarthy B., Schwander S.K., Chang V., Kotenko S., Donepudi S., Lee J., and Raveche E. Genistein induces G2 arrest in malignant B cells by decreasing IL-10 secretion. Cell Cycle 3 12 (2004) 1597-1605
33. Neville-Webbe H.L., Cross N.A., Eaton C.L., Nyambo R., Evans C.A., Coleman R.E., and Holen I. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Research and Treatment 86 3 (2004) 269-279
34. Ortega A., Rámila D., Ardura J.A., Esteban V., Ruiz-Ortega M., Barat A., Gazapo R., Bosch R.J., and Esbrit P. Role of parathyroid hormone-related protein in tubulointerstitial apoptosis and fibrosis after folic acid-induced nephrotoxicity. Journal of the American Society of Nephrology 17 6 (2006) 1594-1603
35. Pérez-Martínez F.C., Alonso V., Sarasa J.L., Nam-cha S., Vela-Navarrete R., Manzarbeitia F., Calahorra F.J., and Esbrit P. Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of PTHrP and its PTH1 receptor, osteoprotegerin and receptor activator of nuclear factor-KB Ligand. Journal of Clinical Pathology 60 3 (2007) 290-294
36. Pérez-Martínez F.C., Alonso V., Sarasa J.L., Manzarbeitia F., Vela-Navarrete R., Calahorra F.J., and Esbrit P. Receptor activator of nuclear factor-K{green}B ligand (RANKL) as a novel prognostic marker in prostate carcinoma. Histology and Histopathology 23 6 (2008) 709-715
37. Pratap J., Javed A., Languino L.R., van Wijnen A.J., Stein J.L., Stein G.S., and Lian J.B. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Molecular and Cellular Biology 25 19 (2005) 8581-8591
38. Rabbani S.A., Gladu J., Harakidas P., et al. Over-production of parathyroid hormone-related peptide results in increased osteolytic metastasis by prostate cancer cells in vivo. International Journal of Cancer 80 2 (1999) 257-264
39. Theoleyre S., Wittrant Y., Tat S.K., et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodelling. Cytokine & Growth Factor Reviews 15 6 (2004) 457-475
40. Tovar Sepulveda V.A., and Falzon M. Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Regulatory Peptide 105 2 (2002) 109-120
41. Viereck V., Gründker C., Blaschke S., Siggelkow H., Emons G., and Hofbauer L.C. Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. Journal of Cellular Biochemistry 84 (2002) 725-735
42. Winston W.T. Novel agents and targets in managing patients with metastatic prostate cancer. Cancer Control 13 3 (2006) 194-198
43. Wong B.R., Josien R., Lee S.Y., Sauter B., Li H.L., Steinman R.M., and Choi Y. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. Journal of Experimental Medicine 186 12 (1997) 2075-2080
44. Yeung F., Law W.K., Yeh C.H., Westendorf J.J., Zhang Y., Wang R., Kao C., and Chung L.W. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. Journal of Biological Chemistry 277 4 (2002) 2468-2476
45. Yoneda T. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. European Journal of Cancer 34 2 (1998) 240-245
46. Zayzafoon M., Abdulkadir S.A., and McDonald J.M. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. Journal of Biological Chemistry 279 5 (2004) 3662-3670
47. Zhang J., Dai J., Qi Y., Lin D.L., Smith P., Strayhorn C., Mizokami A., Fu Z., Westman J., and Keller E.T. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. Journal of Clinical Investigation 107 10 (2001) 1235-1244
48. Zhou J.R., Gugger E.T., Tanaka T., Guo Y., Blackburn G.L., and Clinton S.K. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. Journal of Nutrition 129 9 (1999) 1628-1635